N,N-diethyl-2,4-dihydroxy-6-(2-(naphthalen-2-yl)ethyl)benzamide

ID: ALA2334672

Chembl Id: CHEMBL2334672

PubChem CID: 71720044

Max Phase: Preclinical

Molecular Formula: C23H25NO3

Molecular Weight: 363.46

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCN(CC)C(=O)c1c(O)cc(O)cc1CCc1ccc2ccccc2c1

Standard InChI:  InChI=1S/C23H25NO3/c1-3-24(4-2)23(27)22-19(14-20(25)15-21(22)26)12-10-16-9-11-17-7-5-6-8-18(17)13-16/h5-9,11,13-15,25-26H,3-4,10,12H2,1-2H3

Standard InChI Key:  VDHNSHKKROVEOA-UHFFFAOYSA-N

Associated Targets(Human)

HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK293 (82097 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Sox18 Transcription factor SOX-18 (84 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 363.46Molecular Weight (Monoisotopic): 363.1834AlogP: 4.52#Rotatable Bonds: 6
Polar Surface Area: 60.77Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 8.13CX Basic pKa: CX LogP: 5.55CX LogD: 5.48
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.68Np Likeness Score: 0.09

References

1. Mamidyala SK, Ramu S, Huang JX, Robertson AA, Cooper MA..  (2013)  Efficient synthesis of anacardic acid analogues and their antibacterial activities.,  23  (6): [PMID:23416004] [10.1016/j.bmcl.2013.01.074]
2.  (2018)  Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases,